These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9070549)

  • 1. Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction.
    Bär FW; Meyer J; Vermeer F; Michels R; Charbonnier B; Haerten K; Spiecker M; Macaya C; Hanssen M; Heras M; Boland JP; Morice MC; Dunn FG; Uebis R; Hamm C; Ayzenberg O; Strupp G; Withagen AJ; Klein W; Windeler J; Hopkins G; Barth H; von Fisenne MJ
    Am J Cardiol; 1997 Mar; 79(6):727-32. PubMed ID: 9070549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pro-urokinase for infarct therapy].
    Spiecker M; Meyer J
    Herz; 1994 Dec; 19(6):326-35. PubMed ID: 7843689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase.
    Tebbe U; Windeler J; Boesl I; Hoffmann H; Wojcik J; Ashmawy M; Rüdiger Schwarz E; von Loewis P; Rosemeyer P; Hopkins G
    J Am Coll Cardiol; 1995 Aug; 26(2):365-73. PubMed ID: 7608436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical profile of saruplase: angiographic findings.
    Meyer J
    Int J Clin Pract Suppl; 1998 Nov; 99():9-15. PubMed ID: 10344035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saruplase is a safe and effective thrombolytic agent; observations in 1,698 patients: results of the PASS study. Practical Applications of Saruplase Study.
    Vermeer F; Bösl I; Meyer J; Bär F; Charbonnier B; Windeler J; Barth H
    J Thromb Thrombolysis; 1999 Aug; 8(2):143-50. PubMed ID: 10436145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patency trials with reteplase (r-PA): what do they tell us?
    Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
    Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
    Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
    Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolytic treatment in acute myocardial infarction.
    Verstraete M
    Circulation; 1990 Sep; 82(3 Suppl):II96-109. PubMed ID: 2118432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of combined administration of saruplase and single-chain alteplase on coronary recanalization in acute myocardial infarction.
    Tranchesi B; Bellotti G; Chamone DF; Verstraete M
    Am J Cardiol; 1989 Jul; 64(3):229-32. PubMed ID: 2500842
    [No Abstract]   [Full Text] [Related]  

  • 11. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
    Gulba DC; Tanswell P; Dechend R; Sosada M; Weis A; Waigand J; Uhlich F; Hauck S; Jost S; Rafflenbeul W; Lichtlen PR; Dietz R
    J Am Coll Cardiol; 1997 Dec; 30(7):1611-7. PubMed ID: 9385884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German Recombinant Plasminogen Activator Study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK).
    Neuhaus KL; von Essen R; Vogt A; Tebbe U; Rustige J; Wagner HJ; Appel KF; Stienen U; König R; Meyer-Sabellek W
    J Am Coll Cardiol; 1994 Jul; 24(1):55-60. PubMed ID: 8006283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators.
    Tebbe U; Michels R; Adgey J; Boland J; Caspi A; Charbonnier B; Windeler J; Barth H; Groves R; Hopkins GR; Fennell W; Betriu A; Ruda M; Mlczoch J
    J Am Coll Cardiol; 1998 Mar; 31(3):487-93. PubMed ID: 9502624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of taprostene in patients with acute myocardial infarction treated with thrombolytic therapy: results of the START study. Saruplase Taprostene Acute Reocclusion Trial.
    Bär FW; Meyer J; Michels R; Uebis R; Lange S; Barth H; Groves R; Vermeer F
    Eur Heart J; 1993 Aug; 14(8):1118-26. PubMed ID: 8404943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14.
    Coulter SA; Cannon CP; Ault KA; Antman EM; Van de Werf F; Adgey AA; Gibson CM; Giugliano RP; Mascelli MA; Scherer J; Barnathan ES; Braunwald E; Kleiman NS
    Circulation; 2000 Jun; 101(23):2690-5. PubMed ID: 10851205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.
    Cannon CP; Gibson CM; McCabe CH; Adgey AA; Schweiger MJ; Sequeira RF; Grollier G; Giugliano RP; Frey M; Mueller HS; Steingart RM; Weaver WD; Van de Werf F; Braunwald E
    Circulation; 1998 Dec 22-29; 98(25):2805-14. PubMed ID: 9860780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction.
    Martínez-Ríos MA; Rosas M; González H; Peña-Duque MA; Martínez-Sánchez C; Gaspar J; García H; Gaxiola E; Delgado L; Carrillo J; Leyva JL; Lupi E;
    Am J Cardiol; 2004 Feb; 93(3):280-7. PubMed ID: 14759375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double-blind, randomized angiographic trial of lanoteplase versus alteplase.
    den Heijer P; Vermeer F; Ambrosioni E; Sadowski Z; López-Sendón JL; von Essen R; Beaufils P; Thadani U; Adgey J; Pierard L; Brinker J; Davies RF; Smalling RW; Wallentin L; Caspi A; Pangerl A; Trickett L; Hauck C; Henry D; Chew P
    Circulation; 1998 Nov; 98(20):2117-25. PubMed ID: 9815865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.